Abstract 1308P
Background
High false positive rates in LDCT screening are an important concern. The study aims to explore the diagnostic performance of different diameter thresholds for various lung nodules to reduce unnecessary follow-up LDCT scans and the waste of medical resources.
Methods
Participants were recruited from the "Guangzhou Lung-Care Project" at the First Affiliated Hospital of Guangzhou Medical University in China between 2017 and 2021. The average transverse diameter of lung nodules was measured by semi-automatic segmentation. Positive outcomes were divided into two groups: outcome 1-lung cancer diagnosis with AAH/AIS, and outcome 2-lung cancer diagnosis without AAH/AIS. We calculated the area under the receiver-operating characteristic curves (AUCs), sensitivity, specificity, positive prediction rate(ppv) and negative prediction rate (NPV) to evaluate the diagnostic performance of lung cancer under each threshold between 5mm to 10mm.
Results
In the first year after LDCT screening, 126 cases of lung cancer (including 13 cases of AAH/AIS) were diagnosed among the participants of 11,705 (5,425 men and 6,280 women; median age 59). Increase the average transverse diameter threshold from 5 to 7mm in all lung nodules (solid, part-solid, non-solid), and gradually increase the AUC in outcome 1 (0.766 to 0.825) and outcome 2 (0.78 to 0.839). From 7 to 10mm, the AUC in outcome 1 (0.825 to 0.764) and outcome 2 (0.839 to 0.778) is gradually reduced. In the outcome 2, when the diameter threshold was increased from 5mm to 8mm, the specificity (60.06% to 90.82%) and ppv (6.57% to 19.02%) increased significantly, the sensitivity was reduced (94.02% to 76.07%). When the diameter threshold was increased from 8mm to 10mm, the sensitivity was significantly reduced (76.07% to 60.68%) and specificity (90.82% to 94.88%) and ppv (19.02% to 25.13%) increased slightly. There is no obvious difference between outcome 1 and outcome 2 in the above indicators.
Conclusions
Our study demonstrates that setting a diameter threshold of 8mm for LDCT screening of lung nodules achieves better overall diagnostic performance, reducing false positives and unnecessary follow-up scans while minimizing medical resource waste.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Wenhua Liang.
Funding
The First Affiliated Hospital of Guangzhou Medical University; China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1300P - Treatment and clinical outcome in recurrent/refractory locally advanced NSCLC following chemoradiotherapy and consolidative durvalumab
Presenter: Georg Evers
Session: Poster session 04
1301P - A prognostic clinical and circulating biomarker model to identify futile chemo-radiotherapy (CRT) in stage III NSCLC
Presenter: Rianne Vaes
Session: Poster session 04
1302P - Treatment outcomes and safety of durvalumab following definitive chemoradiotherapy among patients with stage III NSCLC in Thai populations: A real-world, multi-center observational study
Presenter: Piyada Sitthideatphaiboon
Session: Poster session 04
1303P - Immune-modulating effects on tumor draining lymph nodes following neoadjuvant chemoradiotherapy combined with immunotherapy in patients with T3-4N0-1 NSCLC
Presenter: Ezgi Ulas
Session: Poster session 04
1304P - A structured multidisciplinary approach for diagnosing immune-related pneumonitis in patients undergoing adjuvant durvalumab for stage III non-small cell lung cancer
Presenter: Illaa Smesseim
Session: Poster session 04
1305P - Importance of the resected lung tumor specimen in patients with locally advanced and metastatic non-small cell lung cancer undergoing prior targeted therapy
Presenter: Jeong Uk Lim
Session: Poster session 04
1307P - The Biocartis Idylla GeneFusion Assay (RUO) for lung cancer testing: The experience of testing over 5000 tumours in routine practice
Presenter: Lee Robertson
Session: Poster session 04
1309P - Immune exhaustion in tumor-free lymph nodes of non-small cell lung cancer (NSCLC) patients is associated with performance status and survival
Presenter: Laura Sellmer
Session: Poster session 04
1310P - Loratadine: A potential game-changer in lung cancer treatment with improved survival outcomes
Presenter: Xiwen Liu
Session: Poster session 04
1311P - Understanding the basis for intrinsic resistance to KRASG12C inhibitors
Presenter: Alba Santos Ramos
Session: Poster session 04